Gilead's cystic fibrosis drug aztreonam gets FDA panel nod
This article was originally published in Scrip
Executive Summary
In a 15 to two vote, the US FDA's anti-infective drugs advisory panel said Gilead Sciences provided substantial evidence of the safety and efficacy of its investigational cystic fibrosis treatment Cayston (aztreonam lyophilised for inhalation solution).